Pomerantz Law Firm Issues Investor Alert on Actinium Pharmaceuticals Class Action Lawsuit Deadlines

Investor Alert: Class Action Lawsuit Against Actinium Pharmaceuticals

The Pomerantz Law Firm, a leading firm specializing in corporate, securities, and antitrust class litigation, has recently announced a class action lawsuit against Actinium Pharmaceuticals, Inc. (NYSE: ATNM). This lawsuit is particularly relevant for investors who have experienced losses stemming from their investments in Actinium. The firm is urging affected investors to reach out for guidance on how to join the action and secure their rights.

Understanding the Lawsuit

The primary focus of the class action involves allegations that Actinium Pharmaceuticals and certain officers and directors engaged in securities fraud and other unlawful business practices. This action primarily stems from a press release issued by Actinium on August 5, 2024. The release discussed a regulatory update concerning the Company's Biologics License Application (BLA) for Iomab-B, intended for patients with active relapsed or refractory acute myeloid leukemia (AML).

Within this announcement, the U.S. Food and Drug Administration (FDA) declared that the Phase 3 SIERRA trial results were inadequate to support the BLA filing, despite having met a statistically significant primary endpoint. Following this news, shares of Actinium plummeted approximately 60%, dropping to $2.48 per share. This sharp decline has raised concerns among investors about the authenticity of the company’s previous communications regarding its products and prospects.

Important Deadlines

Investors who purchased or acquired Actinium securities during the Class Period have until May 26, 2025, to seek appointment as Lead Plaintiff in the class action. This involves filing the necessary paperwork with the court to represent the interests of all affected shareholders. Potential claimants are encouraged to contact Danielle Peyton at Pomerantz for more details and guidance.

Why Choose Pomerantz?

Pomerantz LLP has a distinguished reputation, having been founded by the prominent attorney Abraham L. Pomerantz, recognized as the dean of the class action bar. The firm has over 85 years of experience advocating for the rights of victims affected by securities fraud and corporate misconduct. Their track record includes recovering substantial monetary damages for class members, underscoring their commitment to safeguarding investor interests.

If you believe you qualify for the class, or simply want to learn more about the case, consider contacting Pomerantz for a review of your investment and potential eligibility. Investors are advised to include their mailing address, phone number, and details of their share purchases when reaching out.

Conclusion

As Actinium Pharmaceuticals continues to navigate legal challenges and regulatory scrutiny, this class action lawsuit poses significant implications for its investors. Staying informed and acting promptly could protect your rights and potentially lead to compensation. Don’t hesitate to reach out to Pomerantz LLP for expert legal assistance in this pressing situation.

For further information regarding the lawsuit and to join the class action, visit Pomerantz Law Firm's website or contact directly to ensure you do not miss out on this critical opportunity.